2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Pathology, Cell Expansion, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Biological Processes, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric, Neonatal, Young Adult, Animal Model
PAPER

1512 A dual-mechanism degrader integrating BTK-PROTAC and IKZF1/3 molecular glue activity in mantle cell lymphoma

Xiaohui Wang I, Huilai Zhang, PhD2
1 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
2 Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Background
Mantle cell lymphoma (MCL) is characterized by aberrant Bruton tyrosine kinase (BTK) signaling, which drives B-cell receptor (BCR) pathway activation. Although BTK inhibitors have substantially improved clinical outcomes, acquired resistance frequently develops. Proteolysis-targeting chimeras (PROTACs) that induce BTK degradation represent a promising therapeutic strategy.
Methods
We designed and synthesized 24 BTK-PROTACs and screened their anti-tumor activity in MCL cell lines by assessing half-maximal inhibitory concentration (IC50) values and BTK degradation efficiency. RNA-sequencing and molecular analyses were performed to investigate the effects of the lead compound on gene expression and BCR signaling. BTK-mutant cell models and xenograft mouse models were established to evaluate the ability of the BTK-PROTAC to overcome acquired resistance to BTK inhibitors. Pharmacokinetic and in vivo safety studies were conducted in SD rats.
Results
Among the synthesized BTK-PROTACs, C23 exhibited the most potent BTK degradation and anti-proliferative activity across multiple MCL cell lines. C23 induced apoptosis and suppressed tumor growth by promoting ubiquitin–proteasome-mediated BTK degradation, thereby inhibiting BCR signaling and its downstream NF-κB and PI3K–AKT–mTOR pathways. Notably, compared with BGB-16673 and NX-5948, C23 displayed molecular glue-like activity by inducing IKZF1 and IKZF3 degradation, leading to broad transcriptional reprogramming with suppression of oncogenic programs (including the IRF4–MYC axis, MYC targets, E2F targets, and G2/M checkpoint signaling), activation of apoptosis pathways, and enhanced T-cell effector function, including increased IL-2 production. C23 effectively degraded BTK and inhibited the growth of both BTKC481S and BTKL528W mutant cells, and significantly suppressed tumor growth in corresponding xenograft models. Pharmacokinetic analyses demonstrated favorable systemic exposure, extensive tissue distribution, and no evidence of metabolic saturation. In addition, C23 exhibited an excellent in vivo safety profile, with no detectable toxicity in major organs and without compromising immune cell composition, immune function, or overall immune homeostasis.
Conclusion
C23 represents a dual-mechanism degrader that integrates PROTAC-mediated BTK degradation with molecular glue-like degradation of IKZF1 and IKZF3, thereby simultaneously targeting the BTK signaling and IKZF1/3–driven oncogenic transcriptional programs while enhancing T-cell effector function. By overcoming BTK inhibitor resistance in vitro and in vivo, together with its favorable pharmacokinetic profile and excellent safety, C23 provides a promising therapeutic strategy for patients with BTK inhibitor-resistant MCL.
Xiaohui Wang I: No relevant conflicts of interest to declare.